TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31240998
Drug: Manual WCST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual WCST administration
Study: 31240998
Drug: Manual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual and Computerized WCST administration
Study: 27633823
Drug: ePROM questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePROM questionnaire completed monthly
Study: 18930226
Drug: GnRH antagonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonists and recombinant FSH in the luteal phase (group II)
Study: 17573794
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) 3350, 17 g daily for 28 days
Study: 17573794
Drug: Tegaserod, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod, 6 mg b.i.d. for 28 days
Study: 2522746
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 10 ml of autologous blood
Study: 6195761
Drug: Cefuroxime and
Normalized name: cefuroxime and metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime and Cefotaxim (antibiotic prophylaxis)
Study: 30229999
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (<10 ng/mL)
Study: 30229999
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D sufficiency (>20 ng/mL)
Study: 28512725
Drug: Clofibrate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate (50 mg/kg single dose prior to phototherapy)
Study: 30415813
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg/d
Study: 15839466
Drug: Optimised formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised formulation of mefloquine (Mephaquin Lactabs/Test)
Study: 12495804
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg buprenorphine
Study: 12495804
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg buprenorphine
Study: 8091360
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg per day of lisinopril
Study: 8091360
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 20 mg of lisinopril and 12.5 mg of hydrochlorothiazide per day
Study: 73903
Drug: Effervescent activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent activated charcoal (10 g packet containing 5 g activated charcoal) administered 30 min after 75 mg nortriptyline
Study: 73903
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of effervescent activated charcoal
Study: 25810066
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (ISMN, 60 mg single dose, day 5) with cortisol (200 mg per day, days 1-6)
Study: 25810066
Drug: Cortisol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (200 mg per day, days 1-6) with placebo (single dose, day 5)
Study: 21670611
Drug: Intraperitoneal local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal local anesthetic (IPLA) - ropivacaine 75 mg instillation before dissection and 0.2% solution at 4 mL/hour for 3 days postoperative infusion
Study: 21670611
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 0.9% saline solution instillation and infusion
Study: 19553646
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (including rescue PCI or delayed angiography)
Study: 16113435
Drug: Corticosteroid/beta(2)‐agonist combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid/beta(2)‐agonist combination therapy
Study: 9881552
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral ciprofloxacin eight hours before surgery
Study: 7770137
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with midazolam and alfentanil
Study: 7770137
Drug: Conventional inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional inhalation anaesthesia
Study: 2457006
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of ABVD chemotherapy
Study: 2457006
Drug: 2 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of MOPP + 2 cycles of ABVD chemotherapy
Study: 2457006
Drug: Irradiation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation at a low dose (20 Gy) for good responders
Study: 31642426
Drug: Double filtration
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double filtration plasmapheresis (DFPP) combined with methylprednisolone (MP) and cyclophosphamide (CTX) pulse therapy
Study: 31642426
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) and cyclophosphamide (CTX) pulse therapy
Study: 19233003
Drug: 7.5 mL
Normalized name: 7.5 ML Spevigo 60 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mL of 3.5% lidocaine dissolved in fibrin glue (Group A)
Study: 19233003
Drug: 7.5 mL
Normalized name: 7.5 ML Spevigo 60 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mL of lidocaine alone (Group B)
Study: 19233003
Drug: 7.5 mL
Normalized name: 7.5 ML Spevigo 60 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mL of fibrin glue alone (Group C)
Study: 9330125
Drug: Carvedilol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (up to 25 mg twice daily, n = 70)
Study: 12885812
Drug: Paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 100 mg/m2 weekly for 3 of 4 weeks with carboplatin (AUC = 6)
Study: 12885812
Drug: Paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 100 mg/m2 and carboplatin (AUC = 2) weekly for 3 of 4 weeks
Study: 12885812
Drug: Paclitaxel 150
Normalized name: paclitaxel 150 MG per 25 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 150 mg/m2 cycle 1 and 100 mg/m2 cycle 2 and carboplatin (AUC = 2) weekly for 6 of 8 weeks
Study: 12885812
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel therapy (70 mg/m2, 3 of 4 weeks)
Study: 10553410
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (CDDP 16 mg/m2 for 5 days, 5-FU 600 mg/m2/day for 120 hours)
Study: 10553410
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (CDDP 80 mg/m2 on day 1, 5-FU 600 mg/m2/day for 120 hours)
Study: 8897078
Drug: 95 mg
Normalized name: aspirin 195 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95 mg metoprolol and 40 mg pantoprazole (test)
Study: 8897078
Drug: 95 mg
Normalized name: aspirin 195 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95 mg metoprolol and placebo (reference)
Study: 31434775
Drug: German Unidimensional
Normalized name: German cockroach allergenic extract
DrugBank: Blatella germanica (DB10418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: German Unidimensional Self‐Efficacy Scale for Multiple Sclerosis (USE‐MS-G)
Study: 26077874
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (500 mg) with iron tablet
Study: 26077874
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with iron tablet
Study: 16109986
Drug: Two-implant overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant overdentures (IOD)
Study: 10709119
Drug: r‐HuEPO 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO 400 units/kg every alternate day for 10 doses
Study: 2183056
Drug: Tetrahydroaminoacridine (THA)
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydroaminoacridine (THA) 100 mg per day
Study: 28558384
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg intravenous paracetamol
Study: 28558384
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg intravenous paracetamol
Study: 28558384
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg intravenous paracetamol
Study: 28558384
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (all doses combined)
Study: 28558384
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose (control group)
Study: 19134454
Drug: Flunarizine Capsules
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine Capsules
Study: 16702322
Drug: High flavanol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavanol cocoa (326 mg/d)
Study: 16702322
Drug: Low flavanol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flavanol cocoa (27 mg/d)
Study: 15378354
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg tid) with conventional treatment
Study: 15378354
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment alone)
Study: 12575970
Drug: Captopril (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (225 mg/day) before treatment
Study: 12575970
Drug: Captopril (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (225 mg/day) after treatment
Study: 12575970
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (0.154 mol/l at 8 ml/kg/h for 4 h) before captopril
Study: 629218
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation of 300 mg administered daily from the 20th week of gestation until term
Study: 629218
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation of 600 mg administered daily from the 20th week of gestation until term
Study: 25675061
Drug: Dexmedetomidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (5 mcg) with 3 mL of 0.5% hyperbaric bupivacaine
Study: 25675061
Drug: Midazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1 mg) with 3 mL of 0.5% hyperbaric bupivacaine
Study: 25675061
Drug: Control (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.5 mL of 0.9% saline) with 3 mL of 0.5% hyperbaric bupivacaine
Study: 15477437
Drug: Vehicle-control solution
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle-control solution
Study: 9990211
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation (PCS) with propofol (bolus: 0.2 mg.kg‐1, lockout time: 3 min)
Study: 9990211
Drug: Anesthesiologist-controlled sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesiologist-controlled sedation (ACS) with propofol (continuous infusion)
Study: 29061081
Drug: Trazodone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (100 mg)
Study: 23756425
Drug: Septilin® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septilin® tablets for two weeks following scaling and root planing
Study: 20058594
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg plus folic acid 0.4 mg daily (low-dose group)
Study: 20058594
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg combined with folic acid 0.8 mg daily (high-dose group)
Study: 20058594
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg/d alone (control)
Study: 7661123
Drug: Combined doses
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined doses of lutein and beta-carotene
Study: 2759842
Drug: Minimal-therapist-contact cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-therapist-contact cognitive-behavioral therapy
Study: 2759842
Drug: Clinic-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-based cognitive-behavioral therapy
Study: 22230883
Drug: Oral leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leucovorin calcium (2 mg/kg per day; maximum 50 mg per day)
Study: 15378676
Drug: Mirtazapine (34.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (34.1 mg daily)
Study: 15378676
Drug: Sertraline (101.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (101.5 mg daily)
Study: 3288801
Drug: Psychorelaxation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychorelaxation treatment (PRT) using autogenous training, biological feedback, or respiratory relaxation training techniques
Study: 25924841
Drug: Tat 30
Normalized name: vadadustat 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat 30 μg given 3 times
Study: 25924841
Drug: Tat 30
Normalized name: vadadustat 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat 30 μg
Study: 25924841
Drug: Tat 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat 7.5 μg or 30 μg, given 3 or 5 times monthly
Study: 25924841
Drug: Tat 30
Normalized name: vadadustat 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat 30 μg, 3x
Study: 21311365
Drug: Creatine (CR)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (CR) supplementation (20 g·d(‐1) for 1 week and 5 g·d(‐1) thereafter)
Study: 17604500
Drug: Systemic agents
Normalized name: ANTIACNE AGENTS,SYSTEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic agents such as IFN‐alpha or cytotoxic chemotherapy
Study: 17604500
Drug: Streptozocin-based therapy
Normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Streptozocin-based therapy
Study: 17604500
Drug: Agents targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agents targeting the VEGF pathway and mammalian target of rapamycin
Study: 15366593
Drug: Tongluo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongluo capsule (TLC)
Study: 9563981
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (1.5 MU in 1 hour)
Study: 9563981
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin (162 mg daily for 1 month)
Study: 9563981
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of streptokinase and one month of aspirin
Study: 2589003
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose
Study: 9564446
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose
Study: 31526791
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training by a physical therapist (12 weekly sessions starting at ∼9 weeks postpartum)
Study: 31077065
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg/1 mL solution administered as a 5-s intravenous bolus
Study: 18055296
Drug: Lightwand-guided endotracheal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lightwand-guided endotracheal intubation with left hand (group L; n = 80)
Study: 16086927
Drug: Omapatrilat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (40 mg every day)
Study: 10473964
Drug: Topical retinaldehyde
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinaldehyde (RAL)
Study: 31464895
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk containing Lactobacillus paracasei HP7 and Glycyrrhiza glabra, administered once daily for 8 weeks
Study: 31464895
Drug: Placebo (fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (fermented milk only), administered once daily for 8 weeks
Study: 25927622
Drug: Baclofen treatment
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen treatment (up to 60 mg/day)
Study: 23992649
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg benfotiamine once daily for 24 weeks
Study: 24844271
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 24 weeks
Study: 11488769
Drug: Nonmetformin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmetformin therapy
Study: 9754983
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 1 week + NSAID (diclofenac 50 mg bid)
Study: 9754983
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 1 week + NSAID (naproxen 250 mg bid)
Study: 9754983
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 1 week + NSAID (piroxicam 10 mg om)
Study: 9754983
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 1 week
Study: 2959967
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (2 g daily for 4 weeks)
Study: 27143787
Drug: Shared canister
Normalized name: talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shared canister MDI therapy
Study: 27143787
Drug: Single-patient canister
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-patient canister therapy
Study: 25543218
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg/mL) alone for PCA (Group M)
Study: 25543218
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg/mL) combined with dezocine (0.05 mg/mL) at a ratio of 20:1 for PCA (Group MD1)
Study: 25543218
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg/mL) combined with dezocine (0.1 mg/mL) at a ratio of 10:1 for PCA (Group MD2)
Study: 23545914
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel with 4% Quassia amara extract
Study: 23545914
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel with 2% ketoconazole
Study: 23545914
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel with 1% ciclopiroxolamine
Study: 17169231
Drug: Self-collected vaginal-rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-collected vaginal-rectal swabs
Study: 17169231
Drug: Clinician-collected vaginal-rectal
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-collected vaginal-rectal swabs
Study: 12829672
Drug: Motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motexafin gadolinium (MGd) 5 mg/kg/d
Study: 12829672
Drug: Whole-brain radiation
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain radiation therapy (WBRT) 30 Gy
Study: 10626701
Drug: High-velocity, low-amplitude
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-velocity, low-amplitude spinal manipulation plus soft tissue therapy 2 to 3 times in the week before menses for at least 3 cycles
Study: 10626701
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with a spring-loaded adjusting instrument wound down for minimum force
Study: 7555936
Drug: Omeprazole (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (n = 45), initial dose of 80 mg followed by 40 mg every eight hours for four days, then oral administration
Study: 7555936
Drug: Ranitidine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (n = 41), 50 mg every six hours for 12 to 24 hours, then oral administration
Study: 2008873
Drug: Olestra (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra (20 g/d)
Study: 6129179
Drug: Thioctic acid
Normalized name: Thioctic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioctic acid (alpha-lipoic acid), 300 mg/day
Study: 25601342
Drug: Standard-dose chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemoradiotherapy (60 Gy)
Study: 25601342
Drug: High-dose chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemoradiotherapy (74 Gy)
Study: 25601342
Drug: Cetuximab with
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab with standard-dose chemoradiotherapy (60 Gy)
Study: 25601342
Drug: No cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No cetuximab with standard-dose chemoradiotherapy (60 Gy)
Study: 25601342
Drug: High-dose chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemoradiotherapy with cetuximab (74 Gy)
Study: 23784615
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (60,000 IU administered intravenously within 3 hours after PCI)
Study: 23784615
Drug: Standard optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard optimal medical treatment
Study: 21315654
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg preladenant
Study: 21315654
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg preladenant